---
title: "BPC-157: A Complete Evidence-Based Guide"
description: "A science-backed guide to BPC-157 (Body Protection Compound-157) covering mechanisms of action, research-backed benefits, dosage protocols, reconstitution, side effects, and legal status."
image: /images/articles/bpc-157.webp
date: 2026-02-13
category: "Peptide Guides"
tags: ["BPC-157", "body protection compound", "peptides", "gut healing", "tendon repair", "neuroprotection", "research peptides"]
author: "PeptideRundown Team"
---

# BPC-157: A Complete Evidence-Based Guide

BPC-157 is one of the most widely discussed peptides in the research and biohacking communities, and for good reason. With over two decades of published preclinical research suggesting benefits ranging from gut healing to tendon repair, it has attracted significant interest from athletes, clinicians, and researchers alike.

> **Key Takeaways**
>
> - BPC-157 is a 15-amino-acid synthetic peptide derived from a protein in human gastric juice
> - Preclinical research shows benefits for gut healing, tendon repair, neuroprotection, and more
> - It works through angiogenesis, nitric oxide modulation, and growth factor upregulation
> - No large-scale human clinical trials exist as of early 2026
> - The FDA has restricted compounding pharmacy access in the US
> - Common dosing is **250-500 mcg** once or twice daily via subcutaneous injection

But what does the science actually say? This guide breaks down everything the current evidence tells us about BPC-157: what it is, how it works, what it may do, and what we still don't know.

## What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a chain of **15 amino acids**, derived from a protein found in human gastric juice.

Its amino acid sequence is: **Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val**

The "body protection compound" designation comes from its parent protein, which is naturally present in the stomach and appears to play a role in maintaining the integrity of the gastrointestinal lining. BPC-157 is a partial sequence of this larger protein, isolated and studied for its concentrated biological activity.

Unlike many peptides that degrade rapidly in gastric acid, BPC-157 is notable for its stability in the gastrointestinal tract. This property has made it a candidate for both injectable and oral administration in research settings.

The peptide was first characterized by researchers at the University of Zagreb in Croatia, led by Professor Predrag Sikiric. His laboratory has published the majority of the existing literature on BPC-157 since the early 1990s [1].

### Key Facts at a Glance

| Property | Detail |
|---|---|
| **Type** | Synthetic pentadecapeptide (15 amino acids) |
| **Molecular Weight** | ~1,419 Da |
| **Origin** | Partial sequence of human gastric juice protein BPC |
| **Primary Research** | Preclinical (animal models, in vitro) |
| **Human Trials** | Limited; no completed large-scale RCTs as of early 2026 |
| **FDA Status** | Not approved for human use |

## How BPC-157 Works: Mechanisms of Action

BPC-157's mechanisms are complex and not fully elucidated, but research has identified several key pathways.

### Angiogenesis and Blood Vessel Formation

One of BPC-157's most well-documented effects is the promotion of angiogenesis, the formation of new blood vessels. Studies show it upregulates **vascular endothelial growth factor (VEGF)** expression and promotes the VEGF-VEGFR2 signaling pathway [2, 3].

This angiogenic effect is believed to be a central mechanism behind BPC-157's observed benefits in tendon, ligament, muscle, and gut tissue healing.

### Nitric Oxide (NO) System Modulation

BPC-157 interacts with the nitric oxide system in a nuanced way. Research suggests it can counteract both NO excess and NO deficiency, acting as a modulator rather than a simple agonist or antagonist [4].

This is significant because dysregulated NO signaling is implicated in conditions from gastrointestinal ulcers to cardiovascular dysfunction.

### Growth Factor Upregulation

Beyond VEGF, BPC-157 has been shown to influence several growth factors relevant to tissue repair:

- **EGF (Epidermal Growth Factor)** — involved in mucosal healing
- **HGF (Hepatocyte Growth Factor)** — relevant to liver and tissue repair
- **FGF (Fibroblast Growth Factor)** — critical for connective tissue

This broad growth factor engagement may explain why BPC-157 appears to accelerate healing across multiple tissue types [5].

### FAK-Paxillin Pathway

BPC-157 activates the FAK-paxillin signaling pathway, which plays a key role in cell migration, adhesion, and tissue remodeling. These are essential processes in wound healing and tendon repair [6].

### Dopaminergic System Interaction

BPC-157 appears to interact with the dopaminergic system, showing protective effects against dopamine-related neurotoxicity in animal models. Studies have shown it can counteract the effects of both dopamine agonists and antagonists, suggesting a stabilizing or modulatory role [7].

### GABAergic System

There is evidence that BPC-157 interacts with the GABA system, which may contribute to reported anxiolytic-like effects in animal models [8].

## What BPC-157 Can Do: Research-Backed Benefits

> **Important:** The vast majority of BPC-157 research is preclinical, conducted in rodent models or in vitro. While the body of evidence is substantial and consistent, human clinical data remains very limited.

### Gastrointestinal Healing

As a compound derived from gastric juice, BPC-157's strongest evidence base involves the GI tract. It has shown protective and healing effects across multiple GI conditions in animal studies:

- **Ulcer healing** — accelerated healing of gastric, duodenal, and colonic ulcers caused by NSAIDs, alcohol, stress, and surgery [1, 9]
- **IBD models** — reduced inflammation, promoted mucosal healing, and improved clinical scores comparable to standard treatments [10]
- **Anastomosis healing** — accelerated surgical gut healing and reduced adhesion formation [11]
- **Esophageal damage** — protective effects against acid reflux-induced lesions [9]

### Tendon and Ligament Repair

The tendon-healing effects of BPC-157 have generated some of the most interest in the athletic and sports medicine communities.

- **Achilles tendon** — significantly accelerated healing of transected Achilles tendons in rats, with improved biomechanical properties and more organized collagen fiber formation [12]
- **Medial collateral ligament (MCL)** — similar acceleration of healing demonstrated in MCL injury models [13]
- **Mechanism** — effects appear mediated through increased collagen production, tendon fibroblast proliferation, FAK-paxillin pathway activation, and enhanced angiogenesis [6, 12]

### Muscle Healing

BPC-157 has shown positive effects on muscle healing in several injury models:

- **Accelerated recovery** from crush injuries
- **Improved healing** of surgically transected muscles
- **Protective effects** against muscle wasting associated with systemic conditions [14]

### Bone Healing

Limited but promising research suggests BPC-157 may accelerate fracture healing. Studies in rabbit models showed improved bone callus formation and faster radiographic healing following segmental bone defects [15].

### Neuroprotection

BPC-157 has demonstrated several neuroprotective properties in animal models:

- **Traumatic brain injury (TBI)** — reduced brain edema, improved behavioral outcomes, and promoted neuronal survival [16]
- **Peripheral nerve injury** — accelerated nerve regeneration and improved functional recovery following sciatic nerve crush [17]
- **Dopaminergic protection** — counteracted neurotoxic effects in models relevant to Parkinson's-like pathology [7]
- **Serotonin system** — may exert antidepressant-like effects in animal behavioral models [8]

### Cardiovascular Effects

- **Blood pressure regulation** — counteracted both hypertensive and hypotensive states in animal models, suggesting a modulatory effect [4]
- **Arrhythmia** — demonstrated anti-arrhythmic properties, counteracting digitalis-induced arrhythmias [18]
- **Vascular protection** — promotes healthy vascular function and endothelial integrity through NO system and angiogenesis effects

### Liver Protection

BPC-157 has shown hepatoprotective effects in several models of liver damage, including alcohol-induced liver injury and NSAID-induced liver toxicity. It appears to promote liver regeneration and reduce inflammatory markers [19].

### Cytoprotection Against NSAID Damage

One of BPC-157's most consistently demonstrated effects is protection against the damaging effects of NSAIDs. This includes protection of the gastric mucosa, intestinal lining, liver, and brain from NSAID-induced damage [1, 9].

## BPC-157 Dosage: How Much to Take

> **Quick Summary:** Most protocols use **250-500 mcg** once or twice daily via subcutaneous injection, typically for **4-8 weeks**.

### Commonly Referenced Dosage Ranges

| Parameter | Range |
|-----------|-------|
| **Typical dose** | 200-500 mcg per administration |
| **Frequency** | 1-2 times daily |
| **Duration** | Typically 4-8 weeks |
| **Body-weight equivalent** | ~2.5-10 mcg/kg (extrapolated from rodent studies) |

The most commonly discussed human-equivalent dose, extrapolated from the animal literature using allometric scaling, falls in the range of **250-500 mcg once or twice daily**.

### Routes of Administration

- **Subcutaneous injection** — the most common route for systemic effects or localized tissue repair; typically administered near the site of injury when targeting a specific area
- **Oral administration** — discussed primarily for gastrointestinal applications; BPC-157 is notable for its stability in gastric acid, making oral administration a viable research route [1]
- **Intramuscular and intraperitoneal** — used in animal research but less commonly discussed in human contexts

### Cycling

There is no established evidence-based cycling protocol. Some practitioners discuss protocols of 4-6 weeks on followed by a break, but this is based on clinical judgment rather than controlled trial data.

## How to Reconstitute BPC-157 (Step-by-Step)

BPC-157 is typically supplied as a lyophilized (freeze-dried) powder in a sealed vial. It must be reconstituted with a sterile solvent before use. The most common solvent is **bacteriostatic water** (sterile water containing 0.9% benzyl alcohol as a preservative).

Need help with the math? Use our free [Peptide Reconstitution Calculator](https://peptidearc.com/tools/reconstitution) on PeptideArc to get exact measurements instantly. For a detailed walkthrough, see our full [reconstitution guide](/articles/how-to-reconstitute-peptides).

### Step-by-Step Reconstitution

1. **Gather materials** — BPC-157 vial (lyophilized powder), bacteriostatic water, insulin syringe (typically 1 mL / 100 unit), alcohol swabs
2. **Clean the vial tops** — wipe both the BPC-157 vial and the bacteriostatic water vial with alcohol swabs; allow to dry
3. **Draw bacteriostatic water** into the syringe:
   - **5 mg vial + 2 mL BAC water = 2,500 mcg/mL** (each 0.1 mL / 10 units = 250 mcg)
   - **5 mg vial + 1 mL BAC water = 5,000 mcg/mL** (each 0.1 mL = 500 mcg)
4. **Inject the water slowly** into the BPC-157 vial, aiming the stream against the glass wall, not directly onto the powder
5. **Swirl gently** until fully dissolved; do not shake vigorously
6. **Store the reconstituted solution** in the refrigerator (2-8C / 36-46F); do not freeze once reconstituted

For a more detailed walkthrough with dosage calculations, see our [complete peptide reconstitution guide](/articles/how-to-reconstitute-peptides).

### Storage and Stability

| State | Storage | Shelf Life |
|---|---|---|
| **Lyophilized (unreconstituted)** | Refrigerated or frozen | Months to years |
| **Reconstituted (BAC water)** | Refrigerated (2-8C) | 3-4 weeks |

Avoid repeated freeze-thaw cycles, direct sunlight, and temperatures above 8C for extended periods.

## BPC-157 Side Effects and Safety Profile

### What the Research Shows

BPC-157 has demonstrated a remarkably favorable safety profile in preclinical studies:

- **No lethal dose (LD1) could be established** — even at extremely high doses, no mortality was observed in acute toxicity testing [1]
- **No organ toxicity** observed at therapeutic or supratherapeutic doses in subchronic studies
- **No mutagenic or carcinogenic effects** reported in the existing literature

### Reported Side Effects

In the limited clinical reports and community use, reported side effects are generally mild and infrequent:

- **Mild nausea** — more common with oral administration
- **Dizziness or lightheadedness** — rare
- **Injection site reactions** — redness, mild discomfort
- **Headache** — infrequent
- **Fatigue or lethargy** — rare

### Important Caveats

- **Limited human data** — no large-scale human clinical trials, so definitive safety claims can't be made
- **Angiogenesis concerns** — blood vessel promotion is a double-edged sword; individuals with active cancer should exercise extreme caution [2]
- **Long-term effects unknown** — most studies examine acute or short-term use only
- **Source quality varies** — contamination and mislabeling are real concerns in the unregulated peptide market
- **Drug interactions possible** — effects on NO, dopaminergic, and other systems suggest potential interactions with medications

> **Important:** Anyone with active malignancies or taking prescription medications should consult a physician before considering BPC-157.

## Is BPC-157 Legal? Current Regulatory Status

### United States (as of 2025-2026)

BPC-157's legal status in the United States has become more restrictive in recent years.

- **FDA classification** — BPC-157 is **not** an FDA-approved drug; it has never completed the approval process for any indication
- **2022-2024 regulatory actions** — the FDA issued warning letters to companies marketing BPC-157 for human use, particularly those making therapeutic claims
- **Compounding pharmacy restrictions** — in late 2023 and into 2024-2025, the FDA placed BPC-157 on its list of substances that cannot be used in compounding under section 503A and 503B, citing insufficient safety and efficacy data
- **Research use** — remains available as a research chemical for in vitro research and non-human use
- **Personal use** — exists in a gray area; purchasing research peptides is not explicitly illegal, but self-administration falls outside FDA-sanctioned use

### International

- **Canada** — available through some compounding pharmacies; regulatory framework differs from the US
- **European Union** — not approved as a pharmaceutical product; available in some countries as a research compound
- **Australia** — classified under the TGA; prescription-level regulation applies
- **WADA** — BPC-157 is **not** currently on the WADA Prohibited List as of 2025, but athletes should verify status regularly

> **Note:** Regulatory status can change. Always verify current regulations in your jurisdiction before purchasing or using any peptide.

## Frequently Asked Questions

### Is BPC-157 natural?

Partially. BPC-157 is a *synthetic* peptide, but its amino acid sequence is derived from a naturally occurring protein found in human gastric juice. The specific 15-amino-acid sequence does not exist as a standalone molecule in the body.

### How quickly does BPC-157 work?

In animal studies, measurable effects on tissue healing have been observed within days, with significant improvements typically documented over 1-4 weeks. Anecdotal human reports are broadly consistent, though individual responses vary.

### Can BPC-157 be taken orally?

Yes. BPC-157 is unusual among peptides in that it demonstrates stability in gastric acid and has shown efficacy via oral administration in animal studies, particularly for gastrointestinal applications [1]. For non-GI targets, subcutaneous injection is more commonly discussed.

### Does BPC-157 need to be injected near the injury site?

This is debated. Some protocols recommend local (perilesional) injection near the injured tissue.

However, animal studies have demonstrated systemic effects even with non-local administration routes, including oral and intraperitoneal [1]. The optimal approach likely depends on the specific application.

### Can BPC-157 be stacked with other peptides?

BPC-157 is frequently discussed in combination with [TB-500 (Thymosin Beta-4 fragment)](/articles/tb-500-complete-guide) for tissue healing applications. While both peptides promote healing through overlapping but distinct mechanisms, there are no controlled studies examining this combination in humans.

### Is BPC-157 safe for long-term use?

Unknown. The existing safety data is drawn from relatively short-term animal studies. The theoretical concern about angiogenesis is particularly relevant in the context of long-term administration.

### Will BPC-157 show up on a drug test?

Standard workplace drug panels do not test for BPC-157. Advanced peptide-specific testing (as may be used by some sports organizations) could potentially detect it. Athletes subject to testing should consult their sport's governing body.

## What We Still Don't Know About BPC-157

1. **Concentration of research** — the majority of studies originate from a single research group (Sikiric et al., University of Zagreb); independent replication would strengthen the evidence
2. **No large human RCTs** — as of early 2026, no completed large-scale randomized controlled trials in humans
3. **Dose translation uncertainty** — extrapolating doses from rodent models to humans using allometric scaling is imperfect
4. **Long-term safety** — the chronic safety profile in any species is not well characterized
5. **Mechanism specificity** — the relative contribution of each pathway to observed effects remains unclear

> **Bottom line:** These gaps don't invalidate the existing research. They underscore the need for caution and intellectual honesty when discussing BPC-157's potential.

## Summary

BPC-157 is a synthetic peptide with an extensive preclinical evidence base suggesting benefits for tissue healing, gastrointestinal protection, neuroprotection, and more. Its mechanisms involve angiogenesis, nitric oxide modulation, growth factor upregulation, and interactions with multiple neurotransmitter systems.

The preclinical safety profile is favorable, with no lethal dose established in rodent studies. However, the lack of large-scale human clinical trials means definitive efficacy and safety claims cannot be made for human use.

As of 2025-2026, BPC-157 faces increasing regulatory restrictions in the United States, particularly regarding compounding pharmacy access. It remains available as a research chemical.

For anyone considering BPC-157, consultation with a knowledgeable healthcare provider is strongly recommended.

New to peptides? Start with our [beginner's guide to peptide therapy](/articles/what-are-peptides-beginners-guide). You can also learn about [peptide side effects](/articles/peptide-side-effects-what-to-know) and [how to store peptides properly](/articles/how-to-store-peptides).

## References

1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. *Curr Pharm Des.* 2014;20(7):1126-1135. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23829361/)

2. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. *J Mol Med.* 2017;95(3):323-333. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27900448/)

3. Tkalcevic VI, Cuzic S, Brajsa K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds. *Eur J Pharmacol.* 2007;570(1-3):212-221. [PubMed](https://pubmed.ncbi.nlm.nih.gov/17628536/)

4. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. *Front Pharmacol.* 2018;9:1408.

5. Vukojevic J, Siroglavic M, Kasnik K, et al. Rat inferior caval vein (ICV) ligature and particular pentadecapeptide BPC 157 therapy. *Vasc Pharmacol.* 2018;106:46-57. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29501668/)

6. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. *J Appl Physiol.* 2011;110(3):774-780. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21030672/)

7. Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease. *Inflammopharmacology.* 2006;14(5-6):214-221. [PubMed](https://pubmed.ncbi.nlm.nih.gov/17091493/)

8. Sikiric P, Rucman R, Turkovic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. *Curr Pharm Des.* 2018;24(18):1990-2001. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29756564/)

9. Sikiric P et al. *Life Sci.* 1994;54(5):PL63-68. [PubMed](https://pubmed.ncbi.nlm.nih.gov/8163129/)

10. Cesarec V, Becejac T, Misic M, et al. Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy. *Eur J Pharmacol.* 2013;701(1-3):203-212. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23220707/)

11. Skorjanec S, Dolovski Z, Kocman I, et al. Therapy for unhealed gastrocutaneous fistulas in rats. *Dig Dis Sci.* 2009;54(12):2602-2611. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19117128/)

12. Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat. *J Orthop Res.* 2006;24(5):1109-1117. [PubMed](https://pubmed.ncbi.nlm.nih.gov/16609979/)

13. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 improves ligament healing in the rat. *J Orthop Res.* 2010;28(9):1155-1161. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20225319/)

14. Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury. *Surg Today.* 2008;38(8):716-725. [PubMed](https://pubmed.ncbi.nlm.nih.gov/18668316/)

15. Sebecic B, Nikolic V, Sikiric P, et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on healing of segmental bone defect in rabbits. *Bone.* 1999;24(3):195-202. [PubMed](https://pubmed.ncbi.nlm.nih.gov/10071910/)

16. Tudor M, Jandric I, Marovic A, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. *Regul Pept.* 2010;160(1-3):26-32. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19931579/)

17. Gjurasin M, Miklic P, Zupancic B, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. *Regul Pept.* 2010;160(1-3):33-41. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19903499/)

18. Barisic I, Balenovic D, Klicek R, et al. Mortal hyperkalemia disturbances in rats are NO-system related. *Regul Pept.* 2013;181:16-26. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23318498/)

19. Ilic S, Brcic I, Mester M, et al. Over-dose insulin and stable gastric pentadecapeptide BPC 157. *J Physiol Pharmacol.* 2009;60 Suppl 7:107-114. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20388953/)

*Last updated: February 13, 2026*

*This article is maintained by the PeptideRundown Team and updated as new research becomes available. If you find an error or have a suggestion, [contact us](/contact).*

*PeptideRundown.com provides evidence-based educational content about peptides. We do not sell peptides, and we are not affiliated with any peptide supplier. Nothing on this site constitutes medical advice.*
